US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Latest News about COMP360

Recent news which mentions COMP360

As Psilocybin Trials Face Delays, Compass Pathways (CMPS) Cuts Workforce To Conserve Cash
Tickers CMPS NEWS
Tags Psychedelics Research Psychedelic Assisted Therapies Market News
From Benzinga
Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder
Tickers CMPS NEWS
Tags News Benzinga Psilocybin
From Benzinga
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
Tickers CMPS
Tags Benzinga CMPS Cannabis
From Benzinga
Compass Pathways Will Lead Two Concurrent Phase 3 Trials On Psilocybin-Assisted Therapy For Depression
Tickers CMPS
Tags Markets Market News Phase 3 Clinical Trial
From Benzinga
Psilocybin For Anorexia: Learn About Compass' Novel Phase 2 Trial Using Magic Mushroom's Main Compound
Tickers CMPS
Tags treatment/resistant depression Psychedelics Anorexia Nervosa
From Benzinga